Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chattem Hopes Brands Acquired From J&J Offset Cool Sales Of Pro-Therapy

This article was originally published in The Tan Sheet

Executive Summary

For 2007, Chattem expects sales of products recently acquired from Johnson & Johnson to rival its existing "big three," of Gold Bond skin care, Icy Hot topical analgesics and Selsun medicated shampoos

You may also be interested in...



Chattem Hopes To Rouse Unisom Sleep Aid Sales

Unisom is alone among Chattem's "big six" brands in not showing sustained sales growth since the firm acquired the sleep aid from Johnson & Johnson

Chattem Hopes To Rouse Unisom Sleep Aid Sales

Unisom is alone among Chattem's "big six" brands in not showing sustained sales growth since the firm acquired the sleep aid from Johnson & Johnson

Chattem Hopes To Rouse Unisom Sleep Aid Sales

Unisom is alone among Chattem's "big six" brands in not showing sustained sales growth since the firm acquired the sleep aid from Johnson & Johnson

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS100223

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel